ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Furthermore, USP47 inhibition subdues the proliferation of K562, K562R (without BCR-ABL mutation and insensitive to IM), and KBM5T315I (with BCR-ABL T315I mutation and insensitive to IM) CML cell lines both in vitro and in vivo.